Want to see ELMD full AI Analyst Report?
ELMD Stock Chart & Stats
$39.34
$1.38(3.59%)
At close: 4:00 PM EDT
$39.34
$1.38(3.59%)
Day’s Range― - ―
52-Week Range$23.01 - $47.40
Previous CloseN/A
Volume19.90K
Average Volume (3M)87.65K
Market Cap
$226.72M
Enterprise Value$349.14
Total Cash (Recent Filing)$20.45M
Total Debt (Recent Filing)$133.00K
Price to Earnings (P/E)20.6
Beta0.81
Next Earnings
Nov 10, 2026EPS Estimate
0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.37
Shares Outstanding8,366,163
10 Day Avg. Volume133,185
30 Day Avg. Volume87,648
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)6.48
Price to Sales (P/S)4.74
P/FCF Ratio41.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$47.00Price Target Upside19.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.48
Revenue Forecast (FY)$83.60M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent double-digit growth across 15 consecutive quarters indicates durable demand for SmartVest and expanding commercial reach. Continued home-care growth provides a scalable base for FY2027, although execution will remain important as the sales force expands.
High And Expanding ProfitabilityStrong gross margins and operating leverage show that Electromed can convert revenue growth into rising profits. Management’s plan to sustain mid-70%+ gross margins supports the durability of earnings, even as it continues investing in sales and R&D.
Payer Coverage And Operating EfficiencyBroader payer access can improve prescription conversion and reduce reimbursement friction, expanding the addressable patient base. Higher electronic-order adoption also shortens fulfillment time, strengthening the direct-sales model and supporting scalable execution.
Bears Say
Single-Product ConcentrationReliance on SmartVest concentrates product, regulatory, reimbursement and execution risk in one platform. An adverse change in clinical perception, payer coverage, product performance or competition could affect most of the company’s revenue until diversification is achieved.
Hospital Channel VolatilityWeak hospital revenue highlights a less predictable channel that may limit near-term diversification beyond home care. Although hospital account liaisons could improve referrals and hospital-to-home transitions, the sales cycle creates ongoing variability in channel growth.
U.S. Market ConcentrationHeavy dependence on the U.S. exposes Electromed to domestic reimbursement, regulatory and healthcare-demand changes. Limited geographic diversification reduces resilience if payer policies shift or U.S. growth slows, despite the supply-chain benefits of domestic manufacturing.
Electromed News
ELMD FAQ
What was Electromed’s price range in the past 12 months?
Electromed lowest stock price was $23.01 and its highest was $47.40 in the past 12 months.
What is Electromed’s market cap?
Electromed’s market cap is $226.72M.
When is Electromed’s upcoming earnings report date?
Electromed’s upcoming earnings report date is Nov 10, 2026 which is in 68 days.
How were Electromed’s earnings last quarter?
Electromed released its earnings results on Aug 25, 2026. The company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.317 by $0.073.
Is Electromed overvalued?
According to Wall Street analysts Electromed’s price is currently Undervalued.
Does Electromed pay dividends?
Electromed does not currently pay dividends.
What is Electromed’s EPS estimate?
Electromed’s EPS estimate is 0.26.
How many shares outstanding does Electromed have?
Electromed has 8,366,163 shares outstanding.
What happened to Electromed’s price movement after its last earnings report?
Electromed reported an EPS of $0.39 in its last earnings report, beating expectations of $0.317. Following the earnings report the stock price went down -19.243%.
Which hedge fund is a major shareholder of Electromed?
Currently, no hedge funds are holding shares in ELMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Electromed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.00 (19.47% Upside)
$47.00 (19.47% Upside)
Blogger Sentiment
Bullish
ELMD Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $782.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Electromed
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
ELMD Company Deck
ELMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong financial and operational performance: record quarterly and annual revenue, expanding margins, significant operating leverage, robust cash flow, expanded payer coverage and sustained sales rep productivity. Key challenges include a sharp quarter-over-quarter decline in hospital revenue, single-product concentration, small but growing R&D investments, and reliance on the U.S. market. Overall, the positives—consistent double-digit growth, improving profitability, cash generation, and clear go-to-market initiatives—significantly outweigh the identifiable risks and execution items.View all ELMD earnings summariesELMD Stock 12 Month Forecast
Average Price Target
$47.00
▲(19.47% Upside)
Technical Analysis
Ownership Overview
7.10% Insiders
10.22% Mutual Funds
12.10% Other Institutional Investors
60.40% Public Companies and
Individual Investors